ICHARUS Study Observing Hemoadsorption Added to Hemodialysis for Adults with Persistent Uremic Symptoms A Real-World Registry on Effectiveness and Safety in Chronic Kidney Disease Stage 5D

What this Trial Is About

Many adults with end-stage kidney disease receiving maintenance hemodialysis still suffer from ongoing uremic symptoms such as itching, fatigue, sleep problems, reduced physical ability, and a lower quality of life, despite optimized dialysis treatments. These symptoms may persist because conventional dialysis methods may not fully remove certain toxins, particularly protein-bound and middle-molecule solutes. The ICHARUS study is a prospective, observational registry designed to evaluate the use of hemodialysis combined with hemoadsorption HAHD in adults with these persistent symptoms. The study enrolls adult patients already receiving maintenance hemodialysis who are prescribed hemoadsorption as part of routine care to help manage uremic symptoms. Hemoadsorption is added to standard dialysis sessions without changing the dialysis type or prescription. The registry collects data without altering treatment, following patients over time as they receive their usual care combined with hemoadsorption. Participants are followed at baseline and during routine visits approximately 1, 3, and 6 months after enrollment. The study collects data on patient symptoms, quality of life, selected lab markers such as serum b22 microglobulin, and safety outcomes related to hemoadsorption. This real-world data aims to describe symptom changes, treatment patterns, tolerability, and safety, helping to improve understanding and guide future research on hemoadsorption in chronic hemodialysis patients.

ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms